Salarius Pharmaceuticals, Inc.

NASDAQ (USD): Salarius Pharmaceuticals, Inc. (SLRX)

Last Price

0.849

Today's Change

+0.017 (2.04%)

Day's Change

0.821 - 0.86

Trading Volume

19,104

Overview

Market Cap

1 Million

Shares Outstanding

2 Million

Avg Volume

263,877

Avg Price (50 Days)

0.79

Avg Price (200 Days)

1.49

PE Ratio

-0.14

EPS

-5.79

Earnings Announcement

07-Aug-2025

Previous Close

0.85

Open

0.86

Day's Range

0.821 - 0.8599

Year Range

0.452 - 7.2

Trading Volume

21,784

Price Change Highlight

1 Day Change

-2.27%

5 Day Change

-1.01%

1 Month Change

22.67%

3 Month Change

-48.09%

6 Month Change

-38.02%

Ytd Change

-52.27%

1 Year Change

-79.03%

3 Year Change

-97.69%

5 Year Change

-99.55%

10 Year Change

-100.00%

Max Change

-100.00%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment